Application of a transcription factor KLF14 in the preparation of products for preventing and treating ischemic stroke

By studying the expression and role of the transcription factor KLF14 in the ischemic stroke model, the problem of unsatisfactory treatment effect in the prior art was solved. It was found that KLF14 has a protective effect on ischemic injury neurons, and is developed. Neuroprotective agents provide new targets and new therapeutic ideas.

CN116549607BActive Publication Date: 2024-11-26NANTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310701064.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-06-14
Publication Date
2024-11-26
Estimated Expiration
2043-06-14

AI Technical Summary

Technical Problem

In the prior art, the pathological mechanism of ischemic stroke is complex and the lack of effective therapeutic drugs and means, resulting in unsatisfactory treatment results.

Method used

In the preparation of ischemic stroke products, the expression and protective effects of KLF14 were studied in the MCAO/R injury model and OGD/R injury neuron model of focal cerebral ischemia and reperfusion in rats. It was found that KLF14 has a protective effect on ischemic-damaged neurons.

Benefits of technology

It was clarified that the expression of KLF14 was significantly increased after ischemic reperfusion injury, which provided a new idea to pretreat acute ischemic stroke, provided a new target for the development of neuroprotective agents, and proved the protective effect of KLF14 on hippocampal neurons.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116549607B_ABST
    Figure CN116549607B_ABST
Patent Text Reader

Abstract

The present invention provides an application of a transcription factor KLF14 in the preparation of a product for preventing and treating ischemic stroke, and relates to the field of biomedical technology. Existing clinical trials of candidate drugs developed for a certain target in the mechanism of cerebral ischemic injury have all failed. By studying new pathological mechanisms and exploring new prevention and treatment targets, it is the direction that scientific researchers have been working hard on. KLF14 is a transcription factor that can be regulated. The present invention confirms that KLF14 is significantly highly expressed in the brain tissue of rats injured by middle cerebral artery occlusion / reperfusion (MCAO / R). The expression of KLF14 in primary cultured hippocampal neurons in vitro is significantly increased after injury by (oxygen and glucose deprivation / reoxygenation, OGD / R); knocking down or overexpressing the expression of KLF14 regulates the expression of KLF14, and the results indicate that KLF14 has a protective effect on neurons injured by OGD / R. The present invention provides a new idea for the pre-treatment of acute ischemic stroke and a new target for the development of neuroprotective agents.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to an application of a transcription factor KLF14 in the preparation of a product for preventing and treating ischemic stroke. Background Art

[0002] Ischemic stroke is a type of cerebrovascular disease that causes focal neurological deficits due to stenosis or occlusion of the cerebral arteries, resulting in a transient lack of blood supply.

[0003] At present, there are many clinical methods for treating ischemic stroke, such as thrombolytic therapy, antiplatelet aggregation therapy, anticoagulant therapy, intravascular intervention therapy, neuroprotective therapy, etc. However, due to the complex pathological mechanism of ischemic stroke, the therapeutic effects of these methods are not particularly effective and ideal. Therefore, in-depth analysis of the pathological mechanism and finding effective therapeutic drugs and methods are one of the key issues that need to be solved urgently. Summary of the invention

[0004] The purpose of the present invention is to solve the technical problem in the prior art that the pathological mechanism of ischemic stroke is complex and there is a lack of effective therapeutic drugs and means.

[0005] In order to achieve the above object, the present invention adopts the following technical solutions:

[0006] Application of a transcription factor KLF14 in the preparation of products for preventing and treating ischemic stroke.

[0007] Preferably, the transcription factor KLF14 provides a protective effect on OGD / R-damaged hippocampal neurons.

[0008] The present application also provides a product for preventing and treating ischemic stroke, comprising the transcription factor KLF14.

[0009] The present application also provides a method for establishing a rat focal cerebral ischemia-reperfusion MCAO / R injury model, and the cerebral ischemia-reperfusion injury model is established using the Longa rat middle cerebral artery occlusion method.

[0010] Preferably, 250-280g SD mice are selected and rats are weighed and intraperitoneally anesthetized, then the rats are fixed on an operating table, the skin is prepared, and after disinfection, the skin is cut along the midline of the neck, and the subcutaneous tissue is separated with ophthalmic forceps; after seeing the trachea, it is separated along the right side, and after seeing the common carotid artery, the common carotid artery is separated and the internal and external carotid branches are found, the proximal end of the common carotid artery is ligated, and the common carotid and external carotid arteries are clamped with artery clamps; a small incision is made with microscissors near the distal end of the ligation, and a wire plug is quickly inserted with microforceps, and the wire plug is ligated and fixed outside the blood vessel at the distal end of the incision, and the clamps clamped on the common carotid and external carotid arteries are removed; the wire plug is continued to be inserted, and it can be stopped when there is resistance, and the wire plug is ligated and fixed to prevent it from falling off.

[0011] Preferably, the rats are kept warm during the model establishment process, and the model is disinfected, sutured and recorded after establishment.

[0012] The present invention uses an ischemic stroke animal model to clarify for the first time that the expression of transcription factor KLF14 increases significantly after ischemic reperfusion injury. Using an OGD / R-induced neuronal injury model, it is demonstrated for the first time that KLF14 expression is significantly high after ischemic injury to hippocampal neurons. It is the first time that transcription factors have been found to have a protective effect on ischemic damaged neurons. The present invention provides a new idea for the pre-treatment of acute ischemic stroke and a new target for the development of neuroprotective agents. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 Schematic diagram of KLF14 gene expression after MCAO / R injury in rats in one embodiment of the present invention, wherein A. TTC staining of brain tissue sections of normal rats and MCAO / R injured rats. White is the injured infarct area. B. Realtime PCR detection of KLF14 expression changes in the penumbra area of ​​the cerebral cortex of normal rats and MCAO / R rats. ;

[0014] Figure 2 2. A schematic diagram of a significant increase in the expression of transcription factor KLF14 after OGD / R injury in primary hippocampal neurons in one embodiment of the present invention, wherein A. Realtime-PCR was used to detect the expression of KLF14 gene in each group after OGD / R injury in primary cultured hippocampal neurons. B. CCK-8 method was used to detect the activity of neurons in each group after OGD / R injury in primary cultured hippocampal neurons.

[0015] In the figure: control group, OGD / R group, blank small interfering RNA + OGD / R group

[0016] (siNC+OGD / R), KLF14 small interfering RNA+OGD / R group (siKLF14+OGD / R), blank overexpression+OGD / R group (OE-NC+OGD / R), KLF14 overexpression+OGD / R group

[0017] (OE-KLF14+OGD / R). DETAILED DESCRIPTION

[0018] The present invention is further described in detail below in conjunction with specific embodiments.

[0019] Application of a transcription factor KLF14 in the preparation of products for preventing and treating ischemic stroke.

[0020] The KLF14 sequence number: (mus) DQ534758.1 (rat) NM_001135094.1

[0021] The transcription factor KLF14 provides protection in hippocampal neurons injured by OGD / R.

[0022] A product for preventing and treating ischemic stroke, comprising transcription factor KLF14.

[0023] The present application also provides a method for establishing a rat focal cerebral ischemia-reperfusion MCAO / R injury model, and the cerebral ischemia-reperfusion injury model is established using the Longa rat middle cerebral artery occlusion method.

[0024] Specifically, in one embodiment, 250-280g SD mice are selected and rats are weighed and intraperitoneally anesthetized, then the rats are fixed on an operating table, the skin is prepared, and after disinfection, the skin is cut along the midline of the neck, and the subcutaneous tissue is separated with ophthalmic forceps; after seeing the trachea, it is separated along the right side, and after seeing the common carotid artery, the common carotid artery is separated and the internal and external carotid branches are found, the proximal end of the common carotid artery is ligated, and the common carotid and external carotid arteries are clamped with artery clamps; a small incision is made with microscissors near the distal end of the ligation, and a wire plug is quickly inserted with microforceps, and the wire plug is ligated and fixed outside the blood vessel at the distal end of the incision, and the clamps clamped on the common carotid and external carotid arteries are removed; the wire plug is continued to be inserted, and it can be stopped when there is resistance, and the wire plug is ligated and fixed to prevent it from falling off.

[0025] The rats were kept warm during the model establishment process, and the model was disinfected, sutured and recorded after establishment.

[0026] The present application is described below in conjunction with specific embodiments:

[0027] Example 1: Establishment of focal cerebral ischemia-reperfusion MCAO / R injury model in rats

[0028] 250-280g SD mice were selected and the cerebral ischemia-reperfusion injury model was established using the Longa's middle cerebral artery occlusion (MCAO) method.

[0029] Specifically, in one embodiment, after the rat is weighed and intraperitoneally anesthetized, the rat is fixed on an operating table, the skin is prepared, the skin is cut along the midline of the neck after disinfection, and the subcutaneous tissue is separated with ophthalmic forceps;

[0030] After seeing the trachea, separate it along the right side. After seeing the common carotid artery, separate the common carotid artery and find the internal and external carotid branches. Ligate the proximal end of the common carotid artery and clamp the common and external carotid arteries with an artery clamp.

[0031] Use microscissors to make a small incision near the distal end of the ligature, and quickly insert the thread plug with micro forceps. Ligate and fix the thread plug outside the blood vessel at the distal end of the incision, and remove the clamps on the common carotid and external carotid arteries.

[0032] Continue to insert the thread plug, stop when there is resistance, and ligate and fix the thread plug to prevent it from falling off. Keep the rat warm during the operation, disinfect and suture, and record.

[0033] Example 2: Primary culture of hippocampal neurons and OGD / R cell injury model:

[0034] In one embodiment, the method can simulate an in vivo cerebral ischemia model, also known as an ex vivo ischemia model.

[0035] Specifically, in one embodiment, a three-gas incubator is used to precisely control the concentrations of CO2 and O2 in the incubator by directly introducing N2, while depriving the neuronal culture medium of sugar, thereby creating an oxygen- and sugar-deficient environment for cultured neurons, simulating the situation of cerebral ischemia in vivo.

[0036] The hippocampal neuron suspension prepared from the hippocampus of fetal rats at 18 days of gestation was inoculated in a cell culture dish and cultured. After 7 days of culture in neuron culture medium (containing 2% B27), the cell culture medium in the culture dish was discarded and replaced with sugar-free culture medium. Then, it was placed in a hypoxic workstation (1% O2, 5% CO2, 94% N2) for 45 minutes of hypoxia culture. The culture dish was removed from the three-gas incubator, and then the sugar-free culture medium was replaced with sugar-containing cell culture medium and placed in the original cell culture incubator for normal culture for different periods of time before detection.

[0037] Example 3: MTT colorimetric assay for detecting hippocampal neuron activity

[0038] Hippocampal neurons were collected at 5 × 10 4 / ml were inoculated in a 96-well culture plate. After culturing for 7 days, OGD was performed for 0.5h, 1h, 2h, 4h, 6h, and 8h, and then 10μl (5mg / ml) of MTT was added to each well and incubated in a 37℃ incubator for 4h.

[0039] After 4 hours, the culture plate was taken out and 100 μl of 20% SDS was added to each well, and then the plate was incubated at 37° C. for 20 hours.

[0040] The optical density (OD) value of each well was detected by an ELISA reader at a wavelength of 570 nm. The experiment was repeated 3 times, and each group was set up with 6 replicate wells each time.

[0041] The cell viability of the normal control group was taken as 100%, and the survival percentage of the cells in each experimental group was calculated. Formula = [cell survival percentage (%) = (cell viability of the injury group ÷ cell viability of the normal control group) × 100%].

[0042] Example 4: RNA extraction from penumbra tissues and cells and detection of KLF14 gene expression (realtime-PCR)

[0043] The rats with successful model were selected, the brains were quickly removed, the blood on the surface was washed off with normal saline, and the brains were frozen at -20°C for 20 min.

[0044] Refer to the method of AshwalS et al. and improve it. Coronal sections were made at 3mm and 9mm from the front of the frontal lobe, and a 6mm thick tissue block was taken from the middle. 1mm coronal sections were cut from the front and back ends for TTC staining (staining in a 37℃ water bath in the dark for 30min) to further confirm the cerebral infarction and determine the sampling site. Figure 1 , Figure 1 The results showed that TTC staining of rat brain sections and the expression of transcription factor KLF14 gene in the infarct area tissue of rats with MCAO / R injury were significantly increased.

[0045] The remaining 4mm brain block was cut from top to bottom at about 2mm from the sagittal suture on the ischemic side to remove the median structure of the ipsilateral hemisphere (this area is supplied by the anterior cerebral artery and is discarded). The remaining ischemic side brain block was cut 2mm from the sagittal section and at a 30° angle to the sagittal section. The outer cortex was the ischemic infarction area and the inner cortex was the ischemic penumbra. The TRIZOL Reagent instructions of Invitrogen were followed. Real-time-PCR was performed using Takara's SYBR PrimeScript RT-PCR Kit, and the operation was performed according to the instructions of the kit (GAPDH was used as an internal reference).

[0046] The results are as follows Figure 2 As shown, Figure 2 The results showed that the expression of transcription factor KLF14 increased significantly after OGD / R injury in primary hippocampal neurons. Transcription factor KLF14 has a protective effect on OGD / R-injured neurons.

[0047] In this application, it is confirmed that KLF14 is significantly highly expressed in the brain tissue of rats injured by middle cerebral artery occlusion / reperfusion (MCAO / R). The expression of KLF14 in primary cultured hippocampal neurons in vitro is significantly increased after injury by (oxygenandglucosedeprivation / reoxygenation, OGD / R); the expression of KLF14 is regulated by knockdown or overexpression, and the results suggest that KLF14 has a protective effect on neurons injured by OGD / R. The present invention provides a new idea for the pre-treatment of acute ischemic stroke and a new target for the development of neuroprotective agents.

Claims

1. The use of transcription factor KLF14 as a neuroprotectant in the preparation of a product for preventing and treating ischemic stroke, characterized in that: The transcription factor KLF14 provides protection in hippocampal neurons injured by OGD / R.